Elite Pharmaceuticals (ELTP) investor relations material

Executive summary

• Achieved record revenues and operating income for Q3 and the first nine months of fiscal 2026, surpassing last year's full-year results in just three quarters.

• Revenue for the nine months ended December 31, 2025, increased 108% year-over-year to $108.1 million, driven by strong growth in manufacturing fees and new product launches, including Lisdexamfetamine and Naltrexone products.

• Net income for the nine months was $26.4 million, a significant turnaround from a net loss of $21.3 million in the prior year period.

• Company now recognized as a reliable supplier with a broad customer base and robust pipeline.

• Reported third quarter fiscal 2026 results with significant revenue and profit growth driven by new product launches and strong performance in existing product lines.

Financial highlights

• Q3 revenue was $31.6M, up 120% year-over-year; nine-month revenue reached $108M, a 104% increase.

• Gross profit for Q3 was $13M (up 112% YoY); nine-month gross profit was $54M (up 138% YoY).

• Operating income for Q3 was $9M (up 721% YoY); nine-month operating income was $39M (up 361% YoY).

• Net income totaled $18.6 million for Q3 and $26.4 million for the nine months.

• Operating cash flow for nine months was $14.6M, up 313% YoY; cash and equivalents at period end were $21.1M.

Outlook and guidance

• Fiscal 2026 is projected to be the best year ever, with expected full-year revenue of $130M–$140M.

• Growth expected to continue, though not at the same doubling rate as previous years.

• R&D spending anticipated to rise in 2026 due to multiple planned projects and filings.

• Launches of methadone and Ritalin generics planned for Q1 and Q2 of 2026, respectively.

• Ongoing litigation and regulatory reviews may impact the timing of new product launches.